02 June 2026
02 June 2026
The companies anticipate finalising the acquisition in the third quarter of 2026.
A number of companies presented new data on their cancer vaccine candidates at ASCO 2026.
The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease.
As the first-to-market DPP-1 inhibitor, Brinsupri is on course to become the standard of care in bronchiectasis treatment.
The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.
The new application was based on results from the Phase III SCOUT-HCM trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
